227 related articles for article (PubMed ID: 37380368)
21. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
22. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
23. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.
Zhao Y; Ruan X; Cheng J; Xu X; Gu M; Mueck AO
Climacteric; 2023 Apr; 26(2):135-142. PubMed ID: 36724820
[TBL] [Abstract][Full Text] [Related]
24. Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer.
Brobbey C; Yin S; Liu L; Ball LE; Howe PH; Delaney JR; Gan W
Sci Rep; 2023 Jul; 13(1):10752. PubMed ID: 37400460
[TBL] [Abstract][Full Text] [Related]
25. Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Chu M; An X; Fu C; Yu H; Zhang D; Li Q; Man X; Dai X; Li Z
Front Biosci (Landmark Ed); 2023 Aug; 28(8):186. PubMed ID: 37664913
[TBL] [Abstract][Full Text] [Related]
26. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
27. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract][Full Text] [Related]
28. High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer.
Lee YS; Kang J; Jung ES; Lee A
J Breast Cancer; 2023 Oct; 26(5):461-478. PubMed ID: 37926068
[TBL] [Abstract][Full Text] [Related]
29. PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer.
Qi L; Sun B; Yang B; Lu S
Breast Cancer Res Treat; 2022 Jun; 193(2):305-318. PubMed ID: 35325342
[TBL] [Abstract][Full Text] [Related]
30.
Emmanuel N; Li H; Chen J; Zhang Y
Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074
[TBL] [Abstract][Full Text] [Related]
31. A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis.
Zhao P; Song H; Gao F; Chen L; Qiu J; Jin J; Pan C; Tang Y; Chen M; Pan Y; Li Y; Huang L; Yang J; Hao X
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110625
[TBL] [Abstract][Full Text] [Related]
32. Natural compound So-2 suppresses triple-negative breast cancer through inducing ferroptosis via downregulating transcription factor E2F7.
Liu N; Jing Z; Wen-Qi D; Ting-Ting L; Cong W; Li-Na H; Feng-Ying Y; Hong-Wei Y; Di G
Arch Biochem Biophys; 2023 Aug; 744():109694. PubMed ID: 37481196
[TBL] [Abstract][Full Text] [Related]
33. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers.
Koppula P; Lei G; Zhang Y; Yan Y; Mao C; Kondiparthi L; Shi J; Liu X; Horbath A; Das M; Li W; Poyurovsky MV; Olszewski K; Gan B
Nat Commun; 2022 Apr; 13(1):2206. PubMed ID: 35459868
[TBL] [Abstract][Full Text] [Related]
34. High Intensity Focused Ultrasound-Driven Nanomotor for Effective Ferroptosis-Immunotherapy of TNBC.
Yu X; Li X; Chen Q; Wang S; Xu R; He Y; Qin X; Zhang J; Yang W; Shi L; Lu L; Zheng Y; Pang Z; Peng S
Adv Sci (Weinh); 2024 Apr; 11(15):e2305546. PubMed ID: 38342612
[TBL] [Abstract][Full Text] [Related]
35. Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer.
Fang K; Xu Z; Jiang S; Yan C; Tang D; Huang Y
Front Immunol; 2022; 13():985861. PubMed ID: 36505498
[TBL] [Abstract][Full Text] [Related]
36. SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer.
Wang Y; Pang X; Liu Y; Mu G; Wang Q
Carcinogenesis; 2023 Dec; 44(8-9):708-715. PubMed ID: 37665951
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.
Dakroub R; Huard S; Hajj-Younes Y; Suresh S; Badran B; Fayyad-Kazan H; Dubois T
Breast Cancer (Dove Med Press); 2023; 15():785-799. PubMed ID: 37954171
[TBL] [Abstract][Full Text] [Related]
38. Autophagy Inhibition Plays a Protective Role in Ferroptosis Induced by Alcohol via the p62-Keap1-Nrf2 Pathway.
Zhao Y; Lu J; Mao A; Zhang R; Guan S
J Agric Food Chem; 2021 Aug; 69(33):9671-9683. PubMed ID: 34388345
[TBL] [Abstract][Full Text] [Related]
39. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
40. PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer.
Noureddine LM; Ablain J; Surmieliova-Garnès A; Jacquemetton J; Pham TH; Marangoni E; Schnitzler A; Bieche I; Badran B; Trédan O; Hussein N; Le Romancer M; Poulard C
Life Sci Alliance; 2023 Oct; 6(10):. PubMed ID: 37536978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
